Re: ZEN-3694 Single Agent Trial Status
in response to
by
posted on
Jan 16, 2018 12:22AM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
narmac - I hear you and agree however, having the ability to negotiate with a potential purchaser without your direct competitors knowing what their competition actually has is sometimes an advantage. I certainly hope this is the case. I was the one who brought this concern to the for after their presentation last week when the chart on side 18 had not been updated from what we saw at the AGM, slide 17. For all we know there could be a bidding war going on between 2 or 3 companies at this time. The big challenge of course is that we just don't know and it's frustrating the heck out of some of us. I am definetly in that group.
tada